Previous 10 | Next 10 |
While the post-operative pain management market is anticipated to grow, the U.S. is looking for alternatives to traditional opioid administration Endonovo has alternative technologies that allow for effective pain and swelling management, bringing down the need for the administration of o...
Endonovo Therapeutics Inc. (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical(TM) therapeutic devices, this morning announced its appointment of Peter Novak, M.D., Ph.D., to its scientific advisory board. According to the update, Novak is a board-certified neurologist...
WOODLAND HILLS, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical™ therapeutic devices, today announces the appointment of Peter Novak, M.D....
Endonovo Therapeutics (OTCQB: ENDV) , an innovative biotechnology company, recently named Dr. Steven Levin, M.D., to its scientific advisory board. An article further discussing the appointment reads, “‘Dr. Levin’s vast experience with novel therapies in the anesthesiolog...
Proprietary bioelectronic devices developed by Endonovo Therapeutics target patient pain and inflammation while aiding wound recovery SofPulse® safely decreases pain by reducing edema (swelling), which decreases the need for prescription pain medications Endonovo’s wearable ...
Appointment of Dr. Steven Levin of Johns Hopkins University to Endonovo’s scientific advisory board is expected to help facilitate the introduction of Endonovo’s non-invasive bio-electrical medical devices to hospitals and clinics The global wearable medical devices market i...
As part of its goal to reduce post-operative drug dependence, innovative biotechnology company Endonovo Therapeutics (OTCQB: ENDV) recently revealed plans to get its flagship SofPulse Therapy Device into 600 hospitals within the next 18 months. An article further discussing the company reads...
Endonovo Therapeutics (OTCQB: ENDV) , an innovative biotechnology company, is poised to profit as the wearable medical devices market is forecasted to rapidly increase over the coming years. An article discussing the company reads, “The global wearable medical devices market is anticip...
Endonovo Therapeutics (OTCQB: ENDV) , an innovative biotechnology company, this morning announced the appointment of Steven Levin, M.D., to its scientific advisory board. Per the update, Dr. Levin will assist Endonovo to facilitate the SofPulse(R) introduction to healthcare facilities and fur...
WOODLAND HILLS, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announces the appointment of Steven Lev...
News, Short Squeeze, Breakout and More Instantly...
Endonovo Therapeutics Inc Company Name:
ENDV Stock Symbol:
OTCMKTS Market:
Endonovo Therapeutics Inc Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...